Volume 8, Issue 3, September 2020, Page: 60-63
Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report
Jiaxin Wang, Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Yu Ding, Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Yuhong Lu, Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Jiaxiong Tan, Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Received: Aug. 5, 2020;       Accepted: Aug. 27, 2020;       Published: Sep. 10, 2020
DOI: 10.11648/j.jctr.20200803.12      View  136      Downloads  41
Abstract
Primary lymphoma of prostate is rare representing approximately 0.1% of all non-Hogdk in lymphomas. This type of lymphoma is more common in men with an average age of 60 years old. Dysuria is the most common symptom of prostatic lymphoma, which can lead to misdiagnosis of benign prostatic hyperplasia and adenocarcinoma easily. Besides, PSA was widely considered in the normal range in most patients with prostatic lymphoma, only a few patients showed elevated. We report a case of a 72-year-old primary prostatic diffuse large B-cell lymphoma patient with a significant increasing of PSA, developed Central Nervous System (CNS) symptoms after completing a cycle of R-CHOP therapy. Unfortunately, the patients received R-CHP in combination with high dose immunoglobulin, after a brief relief of CNS symptoms, the similar CNS symptoms returning again later. Involvement of CNS symptoms during therapy represents a serious complication of aggressive lymphoma, which is rare occurring nearly 5% of non-Hodgkin lymphoma and is considered as a high-risk model In conclusions, primary prostatic lymphoma with an increasing of prostatic-specific antigen is a rare case that is easily misdiagnosed. R-CHOP is till the recommended regimen, but other safe and effective alternatives are urgently needed when obvious CNS symptoms occurred during treatment.
Keywords
Lymphoma, Prostate, Chemotherapy, Central Nervous System Symptoms
To cite this article
Jiaxin Wang, Yu Ding, Yuhong Lu, Jiaxiong Tan, Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report, Journal of Cancer Treatment and Research. Vol. 8, No. 3, 2020, pp. 60-63. doi: 10.11648/j.jctr.20200803.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Kumar P, Rahman K, Hussein N, Gupta R, Nityanand S. Primary prostatic non-Hodgkin's lymphoma presenting with features of prostatism. J Cancer Res Ther. 2019; 15 (Supplement): S178-S179.
[2]
Sivaraman A, Rao N, Choubhey S, Adhyam M. Primary prostatic lymphoma in a young male with hiv infection. Indian J Surg Oncol. 2014; 5 (3): 184-185.
[3]
Rao RN, Bansal M, Raghuvanshi S, Ansari MS, Neyaz Z. Diffuse large B-cell non-Hodgkin lymphoma of the prostate presenting with urinary outlet obstruction: A case report. Urol Ann. 2015; 7 (1): 100-103.
[4]
Manabe M, Hayashi Y, Yoshii Y, Mukai S, Sakamoto E, Kanashima H, et al. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation. Gan To Kagaku Ryoho. 2012; 39 (11): 1733-1735.
[5]
Steuter J, Weisenburger DD, Bociek RG, Bierman P, Vose J, Bast M, et al. Non-Hodgkin lymphoma of the prostate. Am J Hematol. 2011; 86 (11): 952-954.
[6]
Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer. 1985; 56 (12): 2932-2938.
[7]
Petkovic I, Stojnev S, Krstic M, Pejcic I, Vrbic S. Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? Vojnosanit Pregl. 2016; 73 (11): 1072-1075.
[8]
Essadi I, Ismaili N, Tazi E, Elmajjaoui S, Saidi A, Ichou M, et al. Primary lymphoma of the head and neck: two case reports and review of the literature. Cases J. 2008; 1 (1): 426.
[9]
Buckstein R, Lim W, Franssen E, Imrie KL. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma. 2003; 44 (6): 955-962.
[10]
Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, et al. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J Hematol Oncol. 2020; 13 (1): 1.
[11]
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377 (26): 2531-2544.
[12]
Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. N Engl J Med. 2017; 377 (8): 783-784.
[13]
Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgk Figure 2. Immunohistochemical characterization of the prostate biopsy sample. A:HE, x400; B: CD20 (+), x400; C:CD79a (+), x400; D:PAX-5 (+), x400; E: CD3 (+), x400; F: CD10 (+), x400; G:MUM1 (+), X400; H:bcl-6 (+), x400. in lymphoma than DLBCL. Blood. 2018; 131 (16): 1809-1819.
Browse journals by subject